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INTRODUCTION
Neuroblastoma is the most common extracranial solid tu-
mor in children. The most important clinical and biologic
prognostic factors currently used to determine treatment are
the age of the patient at diagnosis, stage of disease, N-myc
amplification status, DNA ploidy and Shimada histology
(1-10). Serum markers such as lactate dehydrogenase (LDH),
ferritin and neuron-specific enolase (NSE) also may be pre-
dictive of survival (11-13).
Neuroblastoma may develop at any site of sympathetic
nervous system tissue. Approximately 80% of all neuroblas-
tomas occur within the abdomen (14-16), while other neu-
roblastomas grow in the mediastinum, at cervical and other
rare sites. Tumors originating from different sites might have
different clinical and biological characteristics. Indeed, the
tumor site has been proposed to be prognostically important
in a few studies (14-22). For example, mediastinal tumors
have been reported to be associated with a more favorable
course than are abdominal tumors (14-18). However, there
is limited information on the prognostic significance of tumors
originating from sites other than the abdomen and thorax.
Furthermore, a direct comparison between extra-abdominal
neuroblastomas, including mediastinal tumors, and abdom-
inal neuroblastomas is rare in the medical literature. There-
fore, in the present study, the clinical and biological prognos-
tic characteristics of extra-abdominal neuroblastomas com-
pared to abdominal neuroblastomas were investigated. 
MATERIALS AND METHODS
Patients
From February 1997 to December 2007, all patients who
were newly diagnosed with neuroblastoma at the Samsung
Medical Center were retrospectively reviewed for the present
study. A diagnosis of neuroblastoma was made based on either
histological examination of the tumor specimens or bone mar-
row infiltration by neuroblastoma cells and elevated urine
catecholamine levels. The N-myc copy number was determined
using Southern blot analysis or the quantitative reverse tran-
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Neuroblastoma Originating from Extra-abdominal Sites: 
Association with Favorable Clinical and Biological Features 
Neuroblastomas originating from different sites might have different clinical and bio-
logical characteristics. In the present study, the clinical (age, sex and stage) and
biological (N-myc amplification, Shimada pathology and levels of lactate dehydro-
genase, ferritin and neuron-specific enolase) characteristics of patients with newly
diagnosed neuroblastoma were compared according to the site of tumor origin (extra-
abdominal versus abdominal). The event-free survival rate (EFS) was also com-
pared between the two groups. Among 143 neuroblastomas, 115 tumors originat-
ed from the abdomen, 26 from extra-abdominal sites and 2 from unknown primary
sites. Frequencies of stage 4 tumor and N-myc amplified tumor were lower in the
extra-abdominal group than in the abdominal group (34.6% vs. 60.0%, P=0.019 and
4.2% vs. 45.0%, P<0.001, respectively). Levels of lactate dehydrogenase, ferritin
and neuron-specific enolase were significantly lower in the extra-abdominal group
than in the abdominal group. The probability of 5-yr EFS (±95% confidence inter-
val) was higher in the extra-abdominal group than in the abdominal group (94.4±
10.6% vs. 69.4±9.4%, P=0.026). Taken together, neuroblastomas originating from
extra-abdominal sites might be associated with more favorable clinical and biologi-
cal characteristics and a better outcome than neuroblastomas originating from
abdomen.
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Accepted : 14 July 2008scriptase-polymerase chain reaction. The patients were staged
according to the international staging system (INSS) report-
ed by Brodeur et al. (23) and the extent of the disease was
evaluated using computerized tomography, a technetium-99
bone scan, bilateral bone marrow aspirates and biopsy speci-
mens and an iodine-131 or 123-metaiodobenzylguanidine
scan. Measurement of serum LDH, ferritin, NSE and urine
vanillylmandelic acid (VMA) was part of a routine evaluation
at diagnosis.
Treatment
Table 1 summarizes the treatment plans. Patients were treat-
ed according to age-, stage- and N-myc-related protocols. Brie-
fly, for patients with low-risk tumors, the primary treatment
was surgery with (stage 2) or without (stage 1) postopera-
tive chemotherapy. For patients with intermediate-risk tumors,
preoperative chemotherapy followed by surgery and postop-
erative chemotherapy was the treatment regimen. While
local radiation therapy to the primary site was given only if
gross total tumor removal was not possible in the early peri-
od of the study (diagnosis until December 2003), all patients
received local radiation therapy regardless of resectability
later in the study (diagnosis from January 2004). High-dose
chemotherapy and autologous stem cell rescue (HDCT/
ASCR) was provided when gross tumor persisted despite
the above-mentioned conventional therapies. For patients
with high-risk tumor, HDCT/ASCR was routinely given as
consolidation therapy after preoperative chemotherapy, surgery
and postoperative chemotherapy (24). Thirteen-cis-retinoic
acid was usually administered for 10 cycles (125 mg/m
2/day
for 14 days per every 4 weeks) to treat possible residual
tumor cells for intermediate- and high-risk patients after
completion of the scheduled chemotherapy. For high-risk
patients, immunotherapy using interleukin-2 was given (2
×10
6 U/m
2/day, subcutaneous injection for 5 consecutive
days per every 4 weeks) with or without preceding induction
therapy (3×10
6 U/m
2/day, continuous infusion for 5 con-
secutive days per week for 2 weeks) after HDCT/ASCR. IL-
2 immunotherapy was usually initiated when the platelet
count exceeded 50×10
9/L without a transfusion after HDCT/
ASCR. The first dose of IL-2 was begun on the first day of
the 13-cis-retinoic acid treatment cycle and was applied until
1 yr after HDCT/ASCR (24).
Statistics
The clinical and biological characteristics were compared
according to the site of tumor origin (extra-abdominal versus
abdominal). Regarding the clinical prognostic factors, age,
sex and INSS stage were compared between the two groups.
For the biological prognostic factors, the Shimada classifica-
tion, N-myc amplification (≥3 copies), serum LDH, ferritin,
NSE and urine VMA were compared between the two groups.
Differences in the frequencies of the clinical and biological
factors were compared using the Pearson chi-square test. Dif-
ferences in the levels of tumor markers were compared using
the Mann-Whitney U test. Levels of tumor markers are pre-
sented as the median values along with the ranges. Overall
survival (OS) and event-free survival (EFS) rates along with
95% confidence interval (CI) were estimated using the Kaplan-
Meier method. An event was defined as the occurrence of
relapse/progression or treatment-related death. The differences
in the survival rates between the two groups according to the
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CEDC, cisplatin 60 mg/m
2/day on day 0, etoposide 100 mg/m
2/day on days 2 and 5, doxorubicin 30 mg/m
2/day on day 2 and cyclophophamide 30 mg/
kg/day on days 3 and 4; ICE, ifosfamide 1,200 mg/m
2/day on days 0-4, carboplatin 400 mg/m
2/day on days 0 and 1 and etoposide 100 mg/m
2/day on
days 0-4; N-myc amplified, ≥3 copies; N-myc nonamplified, <3 copies.
*During the early period of study (diagnosis until December 2003), the CEDC regimen was used as the primary treatment; 
� In the late period (diagnosis
from January 2004), alternating CEDC and ICE regimens were used.
Risk-group Risk factors
Preoperative Postoperative 
Local radiation HDCT/ASCR
chemotherapy chemotherapy
Low Stage 1 and 2, Not done Stage 1: None Not done Not done
any age, Stage 2: CEDC×5*
any N-myc or CEDC×3+ICE×3
�
Intermediate Stage 3, any age,  CEDC×5* CEDC×7* If residual tumor  Only if gross tumor persisted
N-myc nonamplified or CEDC×3+ICE×3
� or CEDC×3+ICE×3
� after surgery*  or tumor relapsed
Stage 4, <1 yr, or regardless of 
N-myc nonamplified residual tumor
�
High Stage 3, any age,  CEDC×5* CEDC×1-3* If residual tumor   In all patients
N-myc amplified or CEDC×3+ICE×3
� or CEDC×2+ICE×1
� after surgery* 
Stage 4, <1 yr,  or regardless of 
N-myc amplified residual tumor
�
Stage 4, >1 yr,
any N-myc
Table 1. Age-, stage- and N-myc-related regimens for neuroblastomaclinical and biological factors were compared using the log-
rank test. Statistical significance was accepted when the P
values were less than 0.05.
RESULTS 
Clinical and biological characteristics of all patients at
diagnosis
From February 1997 to December 2007, 143 consecutive
patients were newly diagnosed with neuroblastoma. Among
143 neuroblastomas, 115 (80.4%) tumors originated from
the abdomen, 26 (18.2%) from extra-abdominal sites (thorax
in 21, neck in 4 and orbit in 1) and two (1.4%) from unknown
primary sites. Table 2 lists the clinical and biological char-
acteristics of the 141 patients, except for the two patients
with tumors from unknown primary sites. The median age
at diagnosis of the 141 patients (81 boys and 60 girls) was
25 months (range 1-129), and 101 (71.6%) patients were
over 12 months of age at diagnosis. Sixty-three (44.7%)
tumors were localized (stage 1 in 16 patients, stage 2 in 12
and stage 3 in 35) and 78 (55.3%) tumors were disseminat-
ed (stage 4 in 77 patients and stage 4S in 1). Fifty-one (37.8%)
of 135 tumors analyzed were N-myc amplified (≥3 copies),
and 72 (53.7%) of 134 tumors analyzed had unfavorable Shi-
mada pathology. The number of low-, intermediate- and high-
risk patients were 28 (19.9%), 32 (22.7%), and 81 (57.4%),
respectively. One hundred-eight, 120, 133, and 132 patients
had serum LDH, ferritin, NSE and 24-hr urine VMA mea-
sured preoperatively at diagnosis. The values measured post-
operatively were not included in the analysis. The levels of
the serum LDH, ferritin, NSE and 24-hr urine VMA were a
median of 1,352 (range 176-9,944) IU/L, 142 (10-6,690)
ng/mL, 68 (7-1,081) ng/mL and 5.6 (range 0.1-101.8) mg/day,
respectively.
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*Median (range)
Abdominal Extra-abdominal
P value
(n=115) (n=26)
Sex
Female 48 (41.7%) 12 (46.2%) 0.681
Male 67 (58.3%) 14 (53.8%)
Age
<1 yr 32 (27.8%) 8 (30.8%) 0.764
≥1 yr 83 (72.2%) 18 (69.2%)
INSS stage
Localized (1, 2, 3) 46 (40.0%) 17 (65.4%) 0.019
Disseminated (4, 4S) 69 (60.0%) 9 (34.6%)
N-myc
Nonamplified (<3 copies) 61 (55.0%) 23 (95.8%) < 0.001
Amplified (≥3 copies) 50 (45.0%) 1 (4.2%)
Undetermined 4 2
Shimada pathology
Favorable 48 (44.0%) 11 (56.0%) 0.279
Unfavorable 61 (56.0%) 10 (44.0%)
Undetermined 6 1
Risk-group
Low 19 (16.5%) 9 (34.6%) 0.026
Intermediate 24 (20.9%) 8 (30.8%)
High 72 (62.6%) 9 (34.6)
LDH (IU/L) 1,391 679 <0.001
(436-9,944)* (176-1,983)
Ferritin (ng/mL) 171 36 0.042
(10-3,284) (10-1,129)
NSE (ng/mL) 103 17 <0.001
(7-1,081) (8-308)
Urine VMA (mg/day) 6.2 3.9 0.056
(0.1-101.8) (0.3-46.4)
Table 3. Clinical and biologic characteristics with respect to tumor
origin
LDH, lactate dehydrogenase; NSE, neuron-specific enolase; VMA, vanil-
lylmandelic acid.
No. of  5-yr EFS
P value
patients ±95% CI (%)
Sex
Female 60 76.4±11.8 0.552
Male 81 71.8±11.3
Age 
<1 yr 40 83.6±12.1 0.345
≥1 yr 101 70.2±10.2
INSS stage
Localized (1, 2, 3) 63 90.0±8.5 0.002
Disseminated (4, 4S) 78 62.6±11.8
N-myc
Nonamplified (<3 copies) 84 80.5±10.2 0.029
Amplified (≥3 copies) 51 63.4±14.0
Shimada pathology
Favorable 62 84.8±9.9 0.092
Unfavorable 72 68.0±12.1
Risk-group
Low 28 100.0 0.002
Intermediate 32 85.2±13.7
High 81 62.0±11.7
Site
Abdominal 115 69.4±9.4 0.026
Extra-abdominal 26 94.4±10.6
LDH 
<Median (<1,352 IU/L) 54 70.0±14.6 0.919
≥Median (≥1,352 IU/L) 54 67.5±14.3
Ferritin
<Median (<142 ng/mL) 60 82.5±11.1 0.007
≥Median (≥142 ng/mL) 60 57.4±14.2
NSE
<Median (<68 ng/mL) 66 86.6±9.3 0.004
≥Median (≥68 ng/mL) 67 61.0±13.1
Urine VMA
<Median (<5.6 mg/day) 66 80.6±10.4 0.128
≥Median (≥5.6 mg/day) 66 63.8±13.2
Table 2. The probability of 5-yr EFS rates with respect to the clini-
cal and biological characteristicsS
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Fig. 1. Levels of serum LDH (A), ferritin (B), NSE (C) and 24-hr urine VMA (D) were lower in the extra-abdominal group than in the abdom-
inal group. 
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Treatment
All 16 patients with stage 1 disease received surgery only
and all 12 patients with stage 2 disease received surgery fol-
lowed by postoperative chemotherapy. Among 32 interme-
diate-risk patients, 10 received single or double HDCT/ASCR
because of persistent gross tumor or tumor relapse. All 81
high-risk patients except five patients (progression in 2
patients, early death in 2 and refusal of HDCT/ASCR in 1)
received single or double HDCT/ASCR, or are scheduled to
receive HDCT/ASCR.
Clinical and biological characteristics with respect to the
site of tumor origin
Table 3 shows the clinical and biological characteristics of
the extra-abdominal and abdominal neuroblastomas. As for
sex, there was no difference between the two groups. The me-
dian age at diagnosis in the abdominal and extra-abdominal
group was 28 (range 1-129) months and 22.5 (range 7-74)
months, respectively (P=0.484). In addition, there was no
difference in the number of patients older than 1 yr of age
at diagnosis between the two groups. The frequency of dis-
seminated tumors (stage 4 and 4S) was lower in the extra-
abdominal group than in the abdominal group (34.6% vs.
60.0%, P=0.019). The frequency of N-myc amplified tumors
was also lower in the extra-abdominal group than in the
abdominal group (4.2% vs. 45.0%, P<0.001). Accordingly,
the proportion of high-risk tumors was lower in the extra-
abdominal group than in the abdominal group (34.6% vs.
62.6%, P=0.026). Furthermore, the frequency of unfavorable
Shimada pathology was lower in the extra-abdominal group
than in the abdominal group, albeit this difference was not
significant. The levels of serum LDH, ferritin, NSE and urine
VMA were lower in the extra-abdominal group than in the
abdominal group (median 679 vs. 1,391 IU/L, P<0.001, Fig.
1A; median 36 vs. 171 ng/mL, P=0.042, Fig. 1B; median
17 vs. 103 ng/mL, P<0.001, Fig. 1C; median 3.9 vs. 6.2
mg/day, P=0.056, Fig. 1D). The characteristics of the five
extra-thoracic and extra-abdominal tumors were very simi-
lar to those of thoracic tumors. All five tumors were local-
ized (stage 1 in 1 patient, stage 2 in 2 and stage 3 in 2). All
of four both extra-thoracic and extra-abdominal tumors ana-
lyzed had non-amplified N-myc results. The levels of serum
LDH, ferritin and NSE were very low (median 504 IU/L,
24 ng/mL and 12 ng/mL, respectively).
Treatment outcome with respect to the site of tumor 
origin
Tumors relapsed or progressed in 16 patients and treatment-
related mortality occurred in 14 patients. Therefore, 111 out
of 141 patients remained event free with a median follow-up
of 47 months (range 1-131) from diagnosis. The probability
of 5-yr OS and EFS rate (±95% CI) for all 141 patients was
76.3±8.5% and 73.9±8.1%, respectively. The probability
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test with respect to the clinical and biological characteristics
are listed in Table 2. The probability of 5-yr EFS rate in
patients with extra-abdominal tumors was higher than in
patients with abdominal tumors (94.4±10.6% vs. 69.4±
9.4%, P=0.026). Fig. 2A shows the EFS curves for patients
with extra-abdominal and abdominal tumors. All but one
patient in the extra-abdominal group are currently event free.
When the analysis was confined to only the patients older
than 1 yr of age at diagnosis, the probability of 5-yr EFS rate
was higher in patients with extra-abdominal tumors than in
those with abdominal tumors (92.3±14.5% vs. 65.3±
11.7%, P=0.047, Fig. 2B). Similarly, when the analysis was
confined to only the patients with stage 4 tumors, the prob-
ability of 5-yr EFS rate was higher in patients with extra-abdo-
minal tumors than in those with abdominal tumors (87.5±
22.9% vs. 59.2±12.8%, P=0.133, Fig. 2C), albeit this dif-
ference was not significant. All five patients with both extra-
thoracic and extra-abdominal tumors remained event free with
a median follow-up of 123 months (range 10-131) from
diagnosis.
DISCUSSION
Neuroblastoma may develop at any site of sympathetic
nervous system tissue. Tumors originating from different sties
might have different clinical and biological characteristics.
Indeed, a few studies have reported that the tumor site was
prognostically important in neuroblastoma (14-22). How-
ever, most studies addressing the prognostic significance of
the tumor site of origin compared thoracic neuroblastomas
and others, and found that thoracic neuroblastomas were asso-
ciated with more favorable clinical features than neuroblas-
tomas originating from other sites, including the abdomen
(14-18). The investigators suggested that the clinical features
of rare neuroblastomas, originating from both extra-thoracic
and extra-abdominal sites, might be similar with those of
thoracic neuroblastomas. Therefore, the present study was
designed to determine the differences in the clinical and bio-
logical features between extra-abdominal and abdominal neu-
roblastomas.
We have shown that the biology of extra-abdominal neu-
roblastomas is indeed different from that of abdominal neu-
roblastomas. The results of the present study revealed that
the extra-abdominal neuroblastomas were associated with more
favorable prognostic factors than were the abdominal neurob-
lastomas. Frequencies of disseminated tumors, N-myc ampli-
fied tumors and tumors with unfavorable Shimada patholo-
gy were lower in patients with extra-abdominal tumors com-
pared to those with abdominal tumors. In addition, levels of
the serum LDH, ferritin, NSE and urine VMA were lower
in the extra-abdominal tumors than in the abdominal tumors.
When the analysis was confined to only the patients older
than 1 yr of age at diagnosis, patients with stage 4 tumors
or with high-risk tumors, the levels of LDH and NSE were
significantly lower in patients with extra-abdominal tumors
compared to those with abdominal tumors (data not shown).
The characteristics of both extra-thoracic and extra-abdomi-
nal tumors were very similar to those of thoracic tumors. In
addition, the results of this study demonstrated that patients
with extra-abdominal neuroblastomas had a more favorable
long-term outcome than did the patients with abdominal
neuroblastomas. All patients with both extra-thoracic and
extra-abdominal tumors are currently event free.
It is not clear whether the more favorable outcome with
extra-abdominal tumors could be attributed to their associ-
ation with favorable clinical and biological features, or whether
the extra-abdominal site is an independent favorable prog-
nostic factor; this is because a multivariate Cox analysis was
not possible in the present study because of the small num-
ber of patients. However, the long-term outcome was better
in the patients with extra-abdominal tumors than in patients
with abdominal tumors even when the data was corrected
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Fig. 2. EFS rate with respect to tumor site of origin. A. The probability of 5-yr EFS was higher in patients with extra-abdominal tumors than
in those with abdominal tumors (94.4±10.6% vs. 69.4±9.4%, P=0.026). B. When the analysis was confined to only the patients older
than 1 yr of age at diagnosis, the probability of 5-yr EFS was also higher in patients with extra-abdominal tumor than in those with abdom-
inal tumor (92.3±14.5% vs. 65.3±11.7%, P=0.047). C. Similarly, when the analysis was confined to only the patients with stage 4 tumor,
the probability of 5-yr EFS was higher in patients with extra-abdominal tumors compared to those with abdominal tumors (87.5±22.9%
vs. 59.2±12.8%, P=0.133), however, this difference was not significant.
A B Cfor age at diagnosis, stage or risk-group. 
Prior studies on thoracic neuroblastomas have reported a
female prevalence (2, 15); however, there was no female preva-
lence in the extra-abdominal group in the present study. When
the analysis was confined to only the patients with thoracic
neuroblastomas, there was no female prevalence. According
to the study reported by Morris et al. (14), patients with tho-
racic neuroblastomas were younger than patients with other
sites of origin. However, there was no difference in the age
at diagnosis between the extra-abdominal and abdominal
neuroblastomas in the present study. In addition, when the
analysis was confined to 21 patients with thoracic neuroblas-
tomas, there was no difference in the age at diagnosis when
compared with other neuroblastomas. In the report by Suita
et al. (15), there was also no difference in age between tho-
racic and nonthoracic patients. Adams et al. (16) confirmed
that children with thoracic neuroblastomas have a more favor-
able outcome, and this was not because of earlier clinical pre-
sentation or earlier expression of symptoms.
During the last decade, HDCT/ASCR has improved the
survival of patients with high-risk neuroblastoma (24-29).
Most patients with high-risk tumors in the present study
received tandem HDCT/ASCR and the probability of 5-yr
EFS among the high-risk patients was over 60%. However,
despite the remarkable improvement in the survival rate in
the present study compared to previous studies addressing
the prognostic significance of tumor site in neuroblastoma,
there is still a significant difference in survival between patients
with extra-abdominal neuroblastomas and those with an ab-
dominal origin. This finding suggests that the tumor site of
origin is a prognostic factor even with the most current treat-
ment protocols. 
This is the first study to investigate the differences in the
clinical and biological characteristics between extra-abdom-
inal and abdominal neuroblastomas. The results of the pre-
sent study show that neuroblastomas originating from extra-
abdominal sites are associated with better clinical and bio-
logical characteristics and they are associated with a better
outcome than those originating from the abdomen. Further
study is needed to explain these findings and to determine
whether an extra-abdominal site is an independent favorable
prognostic factor.
ACKNOWLEDGEMENT
We thank the residents and nurses who cared for the pati-
ents, without whom this study would not have been possible.
REFERENCES 
1. Evans AE, D’Angio GJ, Propert K, Anderson J, Hann HW. Prognos-
tic factor in neuroblastoma. Cancer 1987; 59: 1853-9.
2. Coldman AJ, Fryer CJ, Elwood JM, Sonley MJ. Neuroblastoma: influ-
ence of age at diagnosis, stage, tumor site, and sex on prognosis. Can-
cer 1980; 46: 1896-901.
3. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkin-
son JB, Black CT, Gerbing R, Haase GM, Stram DO, Swift P, Lukens
JN. Successful treatment of stage III neuroblastoma based on prospec-
tivebiologic staging: a Children’s Cancer Group study. J Clin Oncol
1998; 16: 1256-64.
4. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Ampli-
fication of N-myc in untreated human neuroblastomas correlates with
advanced disease stage. Science 1984; 224: 1121-4.
5. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY,
Hammond D. Association of multiple copies of the N-myc oncogene
with rapid progression of neuroblastomas. N Engl J Med 1985; 313:
1111-6.
6. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bow-
man LC, Smith EI, Brodeur GM. Clinical relevance of tumor cell
ploidy and N-myc gene amplification in childhood neuroblastoma: a
Pediatric Oncology Group study. J Clin Oncol 1991; 9: 581-91. 
7. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellu-
lar DNA content as a predictor of response to chemotherapy in infants
with unresectable neuroblastoma. N Engl J Med 1984; 311: 231-5.
8. Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba
T, Marsden HB, Misugi K. Histopathologic prognostic factors in neu-
roblastic tumors: definition of subtypes of ganglioneuroblastoma and
an age-linked classification of neuroblastomas. J Natl Cancer Inst
1984; 73: 405-16.
9. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram
DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP. The Inter-
national Neuroblastoma Pathology Classification (the Shimada sys-
tem). Cancer 1999; 86: 364-72.
10. Joshi VV, Cantor AB, Brodeur GM, Look AT, Shuster JJ, Altshuler
G, Larkin EW, Holbrook CT, Silverman JF, Norris HT. Correlation
between morphologic and other prognostic markers of neuroblastoma.
A study of histologic grade, DNA index, N-myc gene copy number,
and lactic dehydrogenase in patients in the Pediatric Oncology Group.
Cancer 1993; 71: 3173-81.
11. Shuster JJ, McWilliams NB, Castleberry R, Nitschke R, Smith EI,
Altshuler G, Kun L, Brodeur G, Joshi V, Vietti T. Serum lactate dehy-
drogenase in childhood neuroblastoma. A Pediatric Oncology Group
recursive partitioning study. Am J Clin Oncol 1992; 15: 295-303. 
12. Hann HW, Evans AE, Siegel SE, Wong KY, Sather H, Dalton A,
Hammond D, Seeger RC. Prognostic importance of serum ferritin
in patients with Stages III and IV neuroblastoma: the Childrens Can-
cer Study Group experience. Cancer Res 1985; 45: 2843-8.
13. Zeltzer PM, Marangos PJ, Sather H, Evans A, Siegel S, Wong KY,
Dalton A, Seeger RC, Hammond D. Prognostic importance of serum
neuron specific enolase in local and widespread neuroblastoma. Prog
Clin Biol Res 1985; 175: 319-29.
14. Morris JA, Shochat SJ, Smith EI, Look AT, Brodeur GM, Cantor AB,
Castleberry RP. Biological variables in thoracic neuroblastoma: a
Pediatric Oncology Group study. J Pediatr Surg 1995; 30: 296-302.
15. Suita S, Tajiri T, Sera Y, Takamatsu H, Mizote H, Ohgami H, Kurosa-
ki N, Hara T, Okamura J, Miyazaki S, Sugimoto T, Kawakami K,
466 K.W. Sung, K.H. Yoo, H.H. Koo, et al.Tsuneyoshi M, Tasaka H, Yano H, Akiyama H, Ikeda K. The char-
acteristics of mediastinal neuroblastoma. Eur J Pediatr Surg 2000;
10: 353-9.
16. Adams GA, Shochat SJ, Smith EI, Shuster JJ, Joshi VV, Altshuler G,
Hayes FA, Nitschke R, McWilliams N, Castleberry RP. Thoracic
neuroblastoma: a Pediatric Oncology Group study. J Pediatr Surg
1993; 28: 372-7.
17. Ha_berle B, Hero B, Berthold F, von Schweinitz D. Characteristics
and outcome of thoracic neuroblastoma. Eur J Pediatr Surg 2002;
12: 145-50.
18. Horiuchi A, Muraji T, Tsugawa C, Nishijima E, Satho S, Takamizawa
S, Misu H, Mabuchi O, Kanagawa K, Fujita M. Thoracic neuroblas-
toma: outcome of incomplete resection. Pediatr Surg Int 2004; 20:
714-8.
19. Cruccetti A, Kiely EM, Spitz L, Drake DP, Pritchard J, Pierro A. Pelvic
neuroblastoma: low mortality and high morbidity. J Pediatr Surg
2000; 35: 724-8.
20. Moukheiber AK, Nicollas R, Roman S, Coze C, Triglia JM. Primary
pediatric neuroblastic tumors of the neck. Int J Pediatr Otorhinolaryn-
gol 2001; 60: 155-61.
21. Abramson SJ, Berdon WE, Ruzal-Shapiro C, Stolar C, Garvin J. Cer-
vical neuroblastoma in eleven infants-a tumor with favorable prog-
nosis. Clinical and radiologic (US, CT, MRI) findings. Pediatr Radi-
ol 1993; 23: 253-7.
22. Berdon WE, Stylianos S, Ruzal-Shapiro C, Hoffer F, Cohen M. Neu-
roblastoma arising from the organ of Zuckerkandl: an unusual site
with a favorable biologic outcome. Pediatr Radiol 1999; 29: 497-502.
23. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castle-
berry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneto
M, Kemshead J, Lampert F, Lee RE, Look AT, Pearson AD, Philip
T, Roald B, Sawada T, Seeger RC, Tsuchida Y, Voute PA. Revisions
of the international criteria for neuroblastoma diagnosis, staging, and
response to treatment. J Clin Oncol 1993; 11: 1466-77.
24. Sung KW, Lee SH, Yoo KH, Jung HL, Cho EJ, Koo HH, Lee SK,
Kim J, Lim DH, Suh YL, Kim DW. Tandem high-dose chemothera-
py and autologous stem cell rescue in patients over 1 year of age with
stage 4 neuroblastoma. Bone Marrow Transplant 2007; 40: 37-45. 
25. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ram-
sayNK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB,
Reynolds CP. Treatment of high-risk neuroblastoma with intensive
chemotherapy, radiotherapy, autologous bone marrow transplanta-
tion, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med
1999; 341: 1165-73.
26. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinker-
ton R, Michon J, Pritchard J, Klingebiel T, Kremens B, Pearson A,
Coze C, Paolucci P, Frappaz D, Gadner H, Chauvin F. Multivariate
analysis of risk factors in stage 4 neuroblastoma patients over the age
of one year treated with megatherapy and stem-cell transplantation:
a report from the European Bone Marrow Transplantation Solid
Tumor Registry. J Clin Oncol 1998; 16: 953-65.
27. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J,
Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero
B. Myeloablative megatherapy with autologous stem-cell rescue ver-
sus oral maintenance chemotherapy as consolidation treatment in
patients with high-risk neuroblastoma: a randomized controlled trial.
Lancet Oncol 2005; 6: 649-58.
28. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K,
Shamberger RC, Pulsipher M, Grupp SA, Diller L. High-risk neurob-
lastoma treated with tandem autologous peripheral-blood stem cell-
supported transplantation: long-term survival update. J Clin Oncol
2006; 24: 2891-6.
29. Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds
M, Geissler G, Marymount MH, Liu D, Kalapurakal JA, Shore RM,
Bardo DM, Schmoldt J, Rademaker AW, Cohn SL. Treatment of
high-risk neuroblastoma with triple-tandem high-dose therapy and
stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol
2002; 20: 2284-92.
Characteristics of Extra-abdominal Neuroblastoma 467